LA
CDLX icon

Lee Ainslie’s Cardlytics CDLX Stock Holding History

Lee Ainslie’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38
Closed -$42K – 696
2021
Q1 		$42K Buy
+38
New +$50.2K ﹤0.01% 653

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACM
Alua Capital Management New York $103M AUM 11.88% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Lee Ainslie's CDLX Position: Q2 2021 in Review

Lee Ainslie sold out of Cardlytics (CDLX) in Q2 2021, closing a stake of 38 shares — an estimated $42K sold.

Lee Ainslie first reported a position in CDLX in Q1 2021 and held it in 1 quarter. The position peaked at $42K in Q1 2021. 189 funds tracked by Wall St. Rank hold CDLX as of Q2 2021.

  • Lee Ainslie reported no remaining Cardlytics position as of Q2 2021 after selling out during the quarter.
  • Lee Ainslie sold 38 Cardlytics shares in Q2 2021, an estimated $42K.
  • Lee Ainslie first reported a position in Cardlytics in Q1 2021 and held it in 1 quarter.
  • Lee Ainslie's Cardlytics position peaked at $42K in Q1 2021.
  • 189 funds tracked by Wall St. Rank held Cardlytics as of Q2 2021.

Based on Maverick Capital's 13F filing for Q2 2021, filed 16 Aug 2021.